Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
- Chamber
- House
- Introduced
- Aug 13, 2025
- Last action
- May 4, 2026 — PRINT NUMBER 9010B
- Session
- 2025-2026
- Momentum
- 53 · Moderate